Nature Communications (Sep 2018)
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
- Qiuhui Li,
- Qu Deng,
- Hsueh-Ping Chao,
- Xin Liu,
- Yue Lu,
- Kevin Lin,
- Bigang Liu,
- Gregory W. Tang,
- Dingxiao Zhang,
- Amanda Tracz,
- Collene Jeter,
- Kiera Rycaj,
- Tammy Calhoun-Davis,
- Jiaoti Huang,
- Mark A. Rubin,
- Himisha Beltran,
- Jianjun Shen,
- Gurkamal Chatta,
- Igor Puzanov,
- James L. Mohler,
- Jianmin Wang,
- Ruizhe Zhao,
- Jason Kirk,
- Xin Chen,
- Dean G. Tang
Affiliations
- Qiuhui Li
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Qu Deng
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Hsueh-Ping Chao
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Xin Liu
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Yue Lu
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Kevin Lin
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Bigang Liu
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Gregory W. Tang
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Dingxiao Zhang
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Amanda Tracz
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Collene Jeter
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Kiera Rycaj
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Tammy Calhoun-Davis
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Jiaoti Huang
- Department of Pathology, Duke University of School of Medicine
- Mark A. Rubin
- Caryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College
- Himisha Beltran
- Caryl and Israel Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College
- Jianjun Shen
- Department of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center
- Gurkamal Chatta
- Department of Medicine, Roswell Park Comprehensive Cancer Center
- Igor Puzanov
- Department of Medicine, Roswell Park Comprehensive Cancer Center
- James L. Mohler
- Department of Urology, Roswell Park Comprehensive Cancer Center
- Jianmin Wang
- Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center
- Ruizhe Zhao
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Jason Kirk
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Xin Chen
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- Dean G. Tang
- Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center
- DOI
- https://doi.org/10.1038/s41467-018-06067-7
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 17
Abstract
The functional significance of the observed heterogeneity of androgen receptor (AR) expression in prostate cancer is unknown. Here the authors show AR expression heterogeneity is associated with distinct castration/enzalutamide responses and identify BCL-2 as a potential therapeutic target in castration-resistant prostate cancer.
